Trials check

1. Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics (Not listed, Milton S. Hershey Medical Center). Who: 18 years and up, up to 75 years. Nearest site: Benaroya Research Institute, Seattle, Washington (0 mi). https://clinicaltrials.gov/study/NCT06401577
2. InvesT1D: Promoting Adolescent Investment in Diabetes Care (Not phased, Harvard Pilgrim Health Care). Who: 12 years and up. Nearest site: Seattle Children's, Seattle, Washington (0 mi). https://clinicaltrials.gov/study/NCT06384911
3. Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (Phase 3, University of Colorado, Denver). Who: 18 years and up, up to 49 years. Nearest site: University of Washington Medicine Diabetes Institute (UWMDI), Seattle, Washington (0 mi). https://clinicaltrials.gov/study/NCT05819138
4. Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG (Phase 2, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)). Who: 4 years and up, up to 34 years. Nearest site: Benaroya Research Institute, Seattle, Washington (0 mi). https://clinicaltrials.gov/study/NCT07216391
5. METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D) (Phase 2, University of Washington). Who: 18 years and up, up to 69 years. Nearest site: University of Washington Medicine Diabetes Institute (UWMDI), Seattle, Washington (0 mi). https://clinicaltrials.gov/study/NCT07699380
6. Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes (Phase 2, University of Washington). Who: 18 years and up. Nearest site: University of Washington, Seattle, Washington (0 mi). https://clinicaltrials.gov/study/NCT05822609
7. SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes (Phase 2, SAb Biotherapeutics, Inc.). Who: 5 years and up, up to 40 years. Nearest site: Benaroya Research Institute at Virginia Mason, Seattle, Washington (0 mi). https://clinicaltrials.gov/study/NCT07187531
8. CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) (Phase 1/Phase 2, COUR Pharmaceutical Development Company, Inc.). Who: 12 years and up, up to 35 years. Nearest site: Benaroya Research Institute, Seattle, Washington (0 mi). https://clinicaltrials.gov/study/NCT06783309
Each trial has its own eligibility rules; the study page lists them and the contact. Talk it over with your doctor before joining.
ClinicalTrials.gov lists what sponsors register; it doesn't rate trials.